245 related articles for article (PubMed ID: 29189042)
1. Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.
Brizmohun Appayya M; Sidhu HS; Dikaios N; Johnston EW; Simmons LA; Freeman A; Kirkham AP; Ahmed HU; Punwani S
Br J Radiol; 2018 Feb; 91(1083):20170645. PubMed ID: 29189042
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial.
Pye H; Singh S; Norris JM; Carmona Echeverria LM; Stavrinides V; Grey A; Dinneen E; Pilavachi E; Clemente J; Heavey S; Stopka-Farooqui U; Simpson BS; Bonet-Carne E; Patel D; Barker P; Burling K; Stevens N; Ng T; Panagiotaki E; Hawkes D; Alexander DC; Rodriguez-Justo M; Haider A; Freeman A; Kirkham A; Atkinson D; Allen C; Shaw G; Beeston T; Brizmohun Appayya M; Latifoltojar A; Johnston EW; Emberton M; Moore CM; Ahmed HU; Punwani S; Whitaker HC
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33924255
[No Abstract] [Full Text] [Related]
3. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
4. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
[TBL] [Abstract][Full Text] [Related]
5. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
Roscigno M; Stabile A; Lughezzani G; Pepe P; Galosi AB; Naselli A; Naspro R; Nicolai M; La Croce G; Aljoulani M; Perugini G; Guazzoni G; Montorsi F; Balzarini L; Sironi S; Da Pozzo LF
Clin Genitourin Cancer; 2020 Dec; 18(6):e698-e704. PubMed ID: 32493676
[TBL] [Abstract][Full Text] [Related]
6. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
[TBL] [Abstract][Full Text] [Related]
7. The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting.
Hansen NL; Barrett T; Koo B; Doble A; Gnanapragasam V; Warren A; Kastner C; Bratt O
BJU Int; 2017 May; 119(5):724-730. PubMed ID: 27488931
[TBL] [Abstract][Full Text] [Related]
8. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
9. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
[TBL] [Abstract][Full Text] [Related]
10. The role of mpMRI and PSA density in patients with an initial negative prostatic biopsy.
Kotb AF; Spaner S; Crump T; Hyndman ME
World J Urol; 2018 Dec; 36(12):2021-2025. PubMed ID: 29808301
[TBL] [Abstract][Full Text] [Related]
11. Risk-Adapted Strategy Combining Magnetic Resonance Imaging and Prostate-Specific Antigen Density to Individualize Biopsy Decision in Patients With PI-RADS 3 ``Gray Zone'' Lesions.
Akpinar C; Oz DK; Oktar A; Suer E; Ozden E; Haliloglu N; Gulpinar O; Gokce MI; Gogus C; Baltaci S
Clin Genitourin Cancer; 2024 Jun; 22(3):102071. PubMed ID: 38555682
[TBL] [Abstract][Full Text] [Related]
12. Likert vs PI-RADS v2: a comparison of two radiological scoring systems for detection of clinically significant prostate cancer.
Khoo CC; Eldred-Evans D; Peters M; Bertoncelli Tanaka M; Noureldin M; Miah S; Shah T; Connor MJ; Reddy D; Clark M; Lakhani A; Rockall A; Hosking-Jervis F; Cullen E; Arya M; Hrouda D; Qazi H; Winkler M; Tam H; Ahmed HU
BJU Int; 2020 Jan; 125(1):49-55. PubMed ID: 31599113
[TBL] [Abstract][Full Text] [Related]
13. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
14. Comparison of different thresholds of PSA density for risk stratification of PI-RADSv2.1 categories on prostate MRI.
Girometti R; Giannarini G; Panebianco V; Maresca S; Cereser L; De Martino M; Pizzolitto S; Pecoraro M; Ficarra V; Zuiani C; Valotto C
Br J Radiol; 2022 Mar; 95(1131):20210886. PubMed ID: 34762506
[TBL] [Abstract][Full Text] [Related]
15. A cohort of transperineal electromagnetically tracked magnetic resonance imaging/ultrasonography fusion-guided biopsy: assessing the impact of inter-reader variability on cancer detection.
Wajswol E; Winoker JS; Anastos H; Falagario U; Okhawere K; Martini A; Treacy PJ; Voutsinas N; Knauer CJ; Sfakianos JP; Lewis SC; Taouli BA; Rastinehad AR
BJU Int; 2020 Apr; 125(4):531-540. PubMed ID: 31762182
[TBL] [Abstract][Full Text] [Related]
16. PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer.
Frisbie JW; Van Besien AJ; Lee A; Xu L; Wang S; Choksi A; Afzal MA; Naslund MJ; Lane B; Wong J; Wnorowski A; Siddiqui MM
Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):347-352. PubMed ID: 35523940
[TBL] [Abstract][Full Text] [Related]
17. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy.
Hansen NL; Kesch C; Barrett T; Koo B; Radtke JP; Bonekamp D; Schlemmer HP; Warren AY; Wieczorek K; Hohenfellner M; Kastner C; Hadaschik B
BJU Int; 2017 Nov; 120(5):631-638. PubMed ID: 27862869
[TBL] [Abstract][Full Text] [Related]
18. Improving the detection rate of prostate cancer in the gray zone of PI-RADS v2 and serum tPSA by using prostate-specific antigen-age volume.
Lu YF; Zhang Q; Chen HY; Chen JY; Pan Y; Xu CC; Xu JX; Yu RS
Medicine (Baltimore); 2019 Jun; 98(26):e16289. PubMed ID: 31261602
[TBL] [Abstract][Full Text] [Related]
19. Avoiding Unnecessary Biopsy after Multiparametric Prostate MRI with VERDICT Analysis: The INNOVATE Study.
Singh S; Rogers H; Kanber B; Clemente J; Pye H; Johnston EW; Parry T; Grey A; Dinneen E; Shaw G; Heavey S; Stopka-Farooqui U; Haider A; Freeman A; Giganti F; Atkinson D; Moore CM; Whitaker HC; Alexander DC; Panagiotaki E; Punwani S
Radiology; 2022 Dec; 305(3):623-630. PubMed ID: 35916679
[TBL] [Abstract][Full Text] [Related]
20. Detection of clinically signifi cant prostate cancer with PIRADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions.
Westphalen AC; Fazel F; Nguyen H; Cabarrus M; Hanley-Knutson K; Shinohara K; Carroll PR
Int Braz J Urol; 2019; 45(4):713-723. PubMed ID: 31136112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
